Research

Exploring bNAbs as

HIV Prevention Tools in India

Exploring bNAbs as

HIV Prevention Tools in India

Overview

YRG MERF, in collaboration with IAVI and USAID, conducted a multi-site study in Delhi and Chennai (2021–22) to understand the potential of broadly neutralizing antibodies (bNAbs) as a next-generation HIV prevention product. The research focused on priority populations - People Who Inject Drugs.

Overview

YRG MERF, in collaboration with IAVI and USAID, conducted a multi-site study in Delhi and Chennai (2021–22) to understand the potential of broadly neutralizing antibodies (bNAbs) as a next-generation HIV prevention product. The research focused on priority populations - People Who Inject Drugs.

Overview

YRG MERF, in collaboration with IAVI and USAID, conducted a multi-site study in Delhi and Chennai (2021–22) to understand the potential of broadly neutralizing antibodies (bNAbs) as a next-generation HIV prevention product. The research focused on priority populations - People Who Inject Drugs.

Objective

To evaluate the potential of broadly neutralising antibodies (bNAbs) as a tool for HIV prevention, concentrating on preferences and practicality among priority populations such as People Who Inject Drugs (PWID) and Female Sex Workers (FSWs).

Objective

To evaluate the potential of broadly neutralising antibodies (bNAbs) as a tool for HIV prevention, concentrating on preferences and practicality among priority populations such as People Who Inject Drugs (PWID) and Female Sex Workers (FSWs).

Objective

To evaluate the potential of broadly neutralising antibodies (bNAbs) as a tool for HIV prevention, concentrating on preferences and practicality among priority populations such as People Who Inject Drugs (PWID) and Female Sex Workers (FSWs).

Activities

Multi-site study in Delhi and Chennai involving end-user surveys, programmatic assessments with healthcare providers and policymakers.

Exploration of product features (e.g., dosing intervals, side effects, delivery methods) and integration with existing HIV services.

Activities

Multi-site study in Delhi and Chennai involving end-user surveys, programmatic assessments with healthcare providers and policymakers.

Exploration of product features (e.g., dosing intervals, side effects, delivery methods) and integration with existing HIV services.

Activities

Multi-site study in Delhi and Chennai involving end-user surveys, programmatic assessments with healthcare providers and policymakers.

Exploration of product features (e.g., dosing intervals, side effects, delivery methods) and integration with existing HIV services.

Outputs

Outputs

Outcomes

Evidence guiding national bNAb introduction strategies.

Emphasis on stigma-free, community-centered models improving uptake and long-term HIV prevention impact.

Outcomes

Evidence guiding national bNAb introduction strategies.

Emphasis on stigma-free, community-centered models improving uptake and long-term HIV prevention impact.

Outcomes

Evidence guiding national bNAb introduction strategies.

Emphasis on stigma-free, community-centered models improving uptake and long-term HIV prevention impact.

Outcomes

Evidence guiding national bNAb introduction strategies.

Emphasis on stigma-free, community-centered models improving uptake and long-term HIV prevention impact.